| Comparison of Bayesian‐derived and first‐order analytic equations for calculation of vancomycin area under the curve KB Olney, KL Wallace, RP Mynatt, DS Burgess, K Grieves, A Willett, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 42 (4 …, 2022 | 16 | 2022 |
| Comparison of the predictive value of area under the curve versus maximum serum concentration of intravenous tobramycin in cystic fibrosis patients treated for an acute … KB Landmesser, EB Autry, BM Gardner, KA Bosko, A Schadler, RJ Kuhn Pediatric Pulmonology 56 (10), 3209-3216, 2021 | 4 | 2021 |
| Expanded utilization of rituximab in paediatric cardiac transplant patients AL Kiskaddon, K Landmesser, J Carapellucci, B Wisotzkey, ... Journal of Clinical Pharmacy and Therapeutics 46 (3), 762-766, 2021 | 4 | 2021 |
| Review of novel β‐lactams and β‐lactam/β‐lactamase inhibitor combinations with implications for pediatric use KB Olney, JK Thomas, WM Johnson Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 43 (7 …, 2023 | 3 | 2023 |
| Time Above All Else: Pharmacodynamic Analysis of β‐Lactams in Critically Ill Patients KB Landmesser, JA Clark, DS Burgess The Journal of Clinical Pharmacology 62 (4), 479-485, 2022 | 2 | 2022 |
| New Ways to Skin a Cat or Still a Cat Chasing Its Tail? Bayesian Vancomycin Monitoring in the ICU AH Flannery, KB Landmesser, RP Mynatt Critical care medicine 49 (10), 1844-1847, 2021 | 1 | 2021 |
| Vancomycin AUC0–24 estimation using first‐order pharmacokinetic methods in pediatric patients HH Brandon, DS Burgess, KL Wallace, EB Autry, KB Olney Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024 | | 2024 |
| Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation KB Olney, JI Howard, DS Burgess The Journal of Clinical Pharmacology, 2024 | | 2024 |
| 1642. Vancomycin AUC24 Estimation Using First Order Pharmacokinetic Methods in Pediatric Patients KL Wallace, D Burgess, KB Olney, H Brandon Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 1476, 2023 | | 2023 |
| 973. Pharmacokinetic/Pharmacodynamic Evaluation and Dose Optimization of Daptomycin in Pediatric Patients with Staphylococcus aureus Bacteremia KB Olney, JI Howard, D Burgess Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 028, 2023 | | 2023 |
| 2554. What’s Weight Got to Do with It? Prospective Pharmacokinetic/Pharmacodynamic Evaluation of Fixed-Dose Daptomycin KB Olney, J Thomas, MP Pai, DR Burgess, W Olney, R Bruning, KA Griffith, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 2171, 2023 | | 2023 |
| 177. Infectious Diseases Consultation Associated with Decreased Mortality in Gram-Negative Bacteremia R Bruning, K Runyon, DR Burgess, S Cotner, KB Olney, J VanHoose, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 250, 2023 | | 2023 |
| Changing times: The impact of gram-negative breakpoint changes over the previous decade WM Johnson, JA Clark, K Olney, DR Burgess, DS Burgess Antimicrobial Stewardship & Healthcare Epidemiology 2 (1), e165, 2022 | | 2022 |
| COMPARISON OF THE PREDICTIVE VALUE OF AREA UNDER THE CURVE VERSUS MAXIMUM PLASMA CONCENTRATION OF INTRAVENOUS TOBRAMYCIN IN CYSTIC FIBROSIS PATIENTS TREATED FOR AN ACUTE … K Landmesser, B Gardner, E Autry, RJ Kuhn PEDIATRIC PULMONOLOGY 55, S248-S248, 2020 | | 2020 |
